StreetInsider.com News Articles

Form 8-K ROCKET PHARMACEUTICALS, For: Jun 10

Fri, 12 Jun 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26638209.html

Form 8-K ROCKET PHARMACEUTICALS, For: Jun 10

Fri, 12 Jun 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26638209.html

Rocket Pharmaceuticals completes $180 million priority review voucher sale

Fri, 12 Jun 2026 07:01:08 -0400

Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) completed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in gross proceeds, according to a company statement.

The FDA granted the voucher in March 2026 following approval of KRESLADI, Rocket's gene therapy for severe leukocyte adhesion deficiency-I, a rare primary immunodeficiency condition.

The biotechnology company reported cash, cash equivalents and investments of $144.4 million as of March 31, 2026. The voucher sale proceeds increased the company's pro forma cash position to approximately $322.6 million, which Rocket expects will fund operations through the second quarter of 2028.

The priority review voucher allows pharmaceutical companies

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Fri, 12 Jun 2026 07:00:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million.

The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency.

As previously reported, before the PRV sale Rocket

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Fri, 12 Jun 2026 07:00:00 -0400

As previously reported, before the PRV sale Rocket

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Fri, 12 Jun 2026 07:00:00 -0400

As previously reported, before the PRV sale Rocket

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Fri, 12 Jun 2026 07:00:00 -0400

As previously reported, before the PRV sale Rocket

Form SC TO-I/A ROCKET PHARMACEUTICALS, Filed by: ROCKET PHARMACEUTICALS, INC.

Thu, 28 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260528/26568818.html

Form SC TO-I/A ROCKET PHARMACEUTICALS, Filed by: ROCKET PHARMACEUTICALS, INC.

Thu, 28 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260528/26568818.html

Form 4 ROCKET PHARMACEUTICALS, For: May 26 Filed by: Militello John

Thu, 28 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260528/26568039.html

Form 4 ROCKET PHARMACEUTICALS, For: May 26 Filed by: Militello John

Thu, 28 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260528/26568039.html

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Thu, 28 May 2026 07:00:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively.

Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and management will host investor meetings at each conference. Participation details are as follows:

Jefferies Global Healthcare Conference
Date: June 4, 2026
Time: 8:10 AM ET

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Thu, 28 May 2026 07:00:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively.

Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and management will host investor meetings at each conference. Participation details are as follows:

Jefferies Global Healthcare Conference
Date: June 4, 2026
Time: 8:10 AM ET

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Thu, 28 May 2026 07:00:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively.

Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and management will host investor meetings at each conference. Participation details are as follows:

Jefferies Global Healthcare Conference
Date: June 4, 2026
Time: 8:10 AM ET

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Thu, 28 May 2026 07:00:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively.

Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and management will host investor meetings at each conference. Participation details are as follows:

Jefferies Global Healthcare Conference
Date: June 4, 2026
Time: 8:10 AM ET

Form 4 ROCKET PHARMACEUTICALS, For: May 21 Filed by: Shah Gaurav

Tue, 26 May 2026 19:47:00 -0400

si-local-file:///var/storage/secattach/20260526/26551907.html

Form 4 ROCKET PHARMACEUTICALS, For: May 21 Filed by: Shah Gaurav

Tue, 26 May 2026 19:47:00 -0400

si-local-file:///var/storage/secattach/20260526/26551907.html

Form 4 ROCKET PHARMACEUTICALS, For: May 19 Filed by: Militello John